Nigral endothelial dysfunction, homocysteine, and Parkinson's disease.
We found increased levels of atherosclerosis-inducing homocysteine in parkinsonian patients with long-term application of levodopa compared with previously untreated parkinsonian patients and controls. We conclude that antiparkinsonian treatment with levodopa promotes occurrence of vascular disease in Parkinson's disease.
T
T
Müller
B
B
Werne
B
B
Fowler
W
W
Kuhn
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects* / Q000378:metabolism; D014652:Vascular Diseases / Q000139:chemically induced*
D000978:Antiparkinson Agents; D006710:Homocysteine; D007980:Levodopa; D002262:Carboxy-Lyases